SecBot SecBot
Insider Cluster (3 insiders) ·Filed Aug 12, 2026

BCAX

Bicara Therapeutics Inc.
NEUTRAL
Impact 4/10
Horizondays Processed3mo ago
Insider cluster: 2 insiders, $629K total
Actionable Insight • Neutral

The insider sales are small relative to market cap and tied to option exercises, making them routine. However, the cluster's proximity to the CEO departure announcement and earnings creates a modest overhang. Monitor for any additional insider sales in the next 30 days; if no further selling occurs, the cluster is likely liquidity-driven and not a signal of deteriorating fundamentals.

DirectionNeutral
Confidencemedium
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$23.63
T+0 close · Aug 12, 2026 · via day close
Latest settled
−63.48%
T+60 · $8.63
Vs SPY
−58.24%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 13 $23.63entry
  2. T+1 · 3mo ago +2.75%α +2.95% · $24.28
  3. T+5 · 3mo ago +3.22%α +5.18% · $24.39
  4. T+20 · 2mo ago −3.47%α −1.72% · $22.81
  5. T+60 · 11d ago −63.48%α −58.24% · $8.63
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Three top executives at Bicara Therapeutics (CEO, President/COO, CFO) executed same-day option exercises and open-market sales on August 10, 2026, totaling $1.15M in sales. This cluster follows the company's Q2 earnings report (net loss $0.82/share, in line with consensus) and the announcement of CEO Claire Mazumdar's planned departure in January 2027. The sales are likely liquidity-driven (option exercise to cover taxes and diversification) rather than a bearish signal, but the timing, one day after earnings and amid a leadership transition, warrants attention.

Key Financial Metrics

Direction
selling
Total Value
$1.1M
Insiders
3

Key Facts

  • CEO Claire Mazumdar sold 10,000 shares for $279,750 on August 10, 2026, following option exercise.
  • President/COO Ryan Cohlhepp sold 18,750 shares for $524,533 on August 10, 2026, following option exercise.
  • CFO Ivan Hyep sold 12,500 shares for $349,591 on August 10, 2026, following option exercise.
  • Total open-market sales by the three executives: $1.15M, representing ~0.07% of BCAX's $1.6B market cap.
  • All sales occurred one day after Bicara's Q2 2026 earnings release and the announcement of CEO Mazumdar's resignation effective January 2027.
  • The cluster includes non-cash derivative exercises (M) and tax-withholding events (F) that have zero economic value.

Financial Impact

Total insider sales of $1.15M, or 0.07% of market cap, trivial relative to company size.

dilution

Risk Factors

  • CEO transition introduces execution risk ahead of the pivotal FORTIFI-HN01 trial interim analysis in mid-2027.
  • Insider sales could be misinterpreted by the market as a lack of confidence, despite being routine.
  • Biotech sector volatility and binary trial outcomes amplify downside risk.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
81% bullish (21 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-BCAX-1786568502572

Track record

26 reports on BCAX

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +5.65% at T+20 after the Apr 15, 2026 report. 1 of 3 went positive at some point.

Filters
  1. Nov 9, 20267d ago Press Release Neutral 4/10 Entry $9.98 Now $9.75 −2.30% settles Dec 8
  2. Nov 4, 202612d ago Institutional Cluster Neutral 2/10 Entry $8.89 Now $9.75 +9.67% settles Dec 3
  3. Nov 4, 202612d ago Press Release Neutral 2/10 Entry $8.89 Now $9.75 +9.67% settles Dec 3
  4. Oct 7, 20265w ago SC 13G/A Neutral 3/10 Entry $16.42 to $8.89 Now $9.75 −40.62% ▼ −45.86% −44.52% vs SPY
  5. Oct 5, 20266w ago Press Release Neutral 2/10 Entry $17.29 to $9.13 Now $9.75 −43.61% ▼ −47.19% −44.73% vs SPY
  6. Sep 22, 20267w ago Institutional Cluster Bullish 4/10 Entry $22.78 to $18.35 Now $9.75 −57.20% ▼ −19.45% −18.89% vs SPY
  7. Aug 25, 202611w ago 8-K Neutral 2/10 Entry $24.73 to $19.78 Now $9.75 −60.57% ▼ −20.02% −20.24% vs SPY
  8. Aug 14, 202613w ago Press Release Neutral 2/10 Entry $24.28 to $23.20 Now $9.75 −59.84% ▼ −4.45% −2.46% vs SPY
  9. Aug 12, 202613w ago Insider Cluster Neutral Not scored Entry $23.63 to $22.81 Now $9.75 −58.74% ▼ −3.47% −1.72% vs SPY
  10. Aug 12, 202613w ago Insider Cluster Neutral 4/10 Viewing Entry $23.63 to $22.81 Now $9.75 −58.74% ▼ −3.47% −1.72% vs SPY
Showing 10 of 26

US Market Status

Market Closed · Opens Wed (11h 11m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 12, 2026